MET inhibitors start on road to recovery

August 01, 2014

Garber et al., 2014, Nature reviews

The failure of a Phase III lung cancer trial of the MET-specific antibody onartuzumab shocked the community and dented hopes for an important anticancer drug class when Genentech announced the results in March. Genentech halted the METLung trial early, after an interim analysis showed that onartuzumab in combination with the epidermal growth factor receptor (EGFR) inhibitor erlotinib did not provide any meaningful benefit over erlotinib alone. ArQule’s putative MET inhibitor tivantinib had failed 18 months earlier in a similar Phase III lung cancer trial. The value of MET as a target in its most promising major indications, lung cancer and gastric cancer (where GlaxoSmithKline’s foretinib failed in Phase II) seemed in doubt. 

Download review here